STAT4d
Chinese biotech says it will start first in vivo beta-thalassemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Business Wire1mon
Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies
Cyrus’ IdeS has a significantly extended half-life, elicits no ADAs in a relevant animal model and demonstrates potent redosability in vivo ... About Cyrus Biotechnology Cyrus Biotechnology ...
FierceBiotech12d
Umoja secures $100M series C to bring more CAR-Ts into the clinic
Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological malignancies, is presenting clinical data from a ...
Nature4y
Rapid intervention—pioneering technology: redefining spinal cord injury treatment
InVivo Therapeutics is a research and clinical-stage biotechnology company focused on the development of technologies for the treatment of spinal cord injuries (SCIs). InVivo’s mission is to ...
Benzinga.com4d
Chinese biotech says it will start first in vivo beta-thalassemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I’m still recovering from yesterday, when Chicago was ...